NCT02676544 is a Phase 1/Phase 2 clinical trial of Embosphere microspheres in Benign Prostatic Hypertrophy, sponsored by Rhode Island Hospital.

Who is sponsoring NCT02676544?

NCT02676544 is sponsored by Rhode Island Hospital.

What drugs are being tested in NCT02676544?

Interventions in NCT02676544: Embosphere microspheres.

What condition does NCT02676544 study?

NCT02676544 studies Benign Prostatic Hypertrophy, Lower Urinary Tract Symptoms.

Is NCT02676544 still recruiting?

NCT02676544 is currently terminated. Last updated 2 July 2021.

Last reviewed 2021-07-02 · How we verify

NCT02676544

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Prostate Embolization for Massive Benign Prostatic Hypertrophy (BPH)

Terminated Phase 1/Phase 2 Last updated 2 July 2021

What this trial tests

Phase 1/Phase 2 trial testing Embosphere microspheres in Benign Prostatic Hypertrophy in 9 participants. Terminated before completion.

Timeline

1 December 2015

Primary endpoint
30 June 2021

30 June 2021

Quick facts

Lead sponsor	Rhode Island Hospital
Phase	Phase 1/Phase 2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	9
Start date	1 December 2015
Primary completion	30 June 2021
Estimated completion	30 June 2021
Sites	1 location across United States

Drugs / interventions tested

Embosphere microspheres

Conditions studied

Benign Prostatic Hypertrophy — all drugs for Benign Prostatic Hypertrophy →
Lower Urinary Tract Symptoms — all drugs for Lower Urinary Tract Symptoms →

Sponsor

Rhode Island Hospital

Who can join

50 and older, male only, with Benign Prostatic Hypertrophy or Lower Urinary Tract Symptoms. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Clinical Improvement in Lower Urinary Tract Symptoms (LUTS)
Time frame: 24 months
Questionnaire

Sponsor's own description

This is a prospective, open label single center feasibility study to demonstrate basic safety and effectiveness of prostate artery embolization for the treatment of symptomatic benign prostatic Hyperplasia (BPH) in a small series of patients with large (≥90 grams) glands.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Rhode Island Hospital trials

Trials by the same sponsor.

NCT06747221 — Implementation Science to Enhance HIV Testing Services During Emergency Care in Kenya · NA · not yet recruiting
NCT07211087 — Improving the Treatment of Depression Among Youth With HIV · NA · not yet recruiting
NCT06754527 — Options for Navigating Talking About Risk and Adolescent Choices · NA · not yet recruiting
NCT07144631 — Peroneal Electrical Nerve Stimulation in Pregnancy for Restless Legs Syndrome · NA · recruiting
NCT06942455 — A Sleep Hygiene Intervention to Improve Sleep Health in Urban, Latino Middle School Children · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02676544 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Rhode Island Hospital
Last refreshed: 2 July 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02676544.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing